Drug Profile

Research programme: amurin peptides based therapeutics - ContraFect

Latest Information Update: 25 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ContraFect
Class Antibacterials; Peptides
Mechanism of Action Cell wall inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Gram-negative infections

Most Recent Events

04 Dec 2023 Discontinued - Preclinical for Gram-negative infections in USA (unspecified route) as ContraFect filed for voluntary bankruptcy under chapter 11 of the US Bankruptcy code
29 May 2021 ContraFect announces intension to file IND submission for Amurin peptides candidate for broad spectrum gram-negative infections in second half of 2021
30 Mar 2021 Preclinical trials in Gram-negative infections in USA by March 2021

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com